PDCD1 and neoplasm: This in turn suggests that combining the anti-PD-1 ICIs currently used in the clinical setting with additional pharmacological agents that promote ILC2 infiltration into the tumor may be a valuable therapeutic strategy for those patients that do not respond to the therapy.